Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. The company has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. The company is continuing its legacy business of manufacturing and selling certain proprietary reagents. The company develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Follow-Up Questions
Who is the CEO of Spectral Medical Inc?
Mr. Chris Seto is the Chief Executive Officer of Spectral Medical Inc, joining the firm since 2019.
What is the price performance of EDTXF stock?
The current price of EDTXF is $1.08, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Spectral Medical Inc?
Spectral Medical Inc belongs to Biotechnology industry and the sector is Health Care
What is Spectral Medical Inc market cap?
Spectral Medical Inc's current market cap is $310.1M
Is Spectral Medical Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Spectral Medical Inc, including 2 strong buy, 2 buy, 1 hold, 0 sell, and 2 strong sell
